Frequently Asked Questions about Entrada Therapeutics, Inc. (TRDA)

Name: Entrada Therapeutics, Inc. (TRDA) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Entrada Therapeutics, Inc. (TRDA) do?

Accepted Answer

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead produ...

Question 2

Is Entrada Therapeutics, Inc. (TRDA) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of TRDA reveals an Altman Z-Score of 3.10 and a Piotroski F-Score of 2/9. These metrics, combined with its 5-year revenue trend ($0.03B most recent), help investors decide if TRDA fits their risk profile.

Question 3

What is the current P/E ratio for TRDA?

Accepted Answer

As of the latest trading session, Entrada Therapeutics, Inc. (TRDA) has a trailing P/E ratio of -3.99.

Question 4

Who is the CEO of Entrada Therapeutics, Inc.?

Accepted Answer

The current Chief Executive Officer of Entrada Therapeutics, Inc. is Dipal Doshi.

Question 5

What was TRDA's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Entrada Therapeutics, Inc. reported annual revenues of $0.03B (2025), $0.21B (2024), $0.13B (2023), $0.00B (2022), $0.00B (2021) respectively.

Question 6

Does TRDA pay a dividend?

Accepted Answer

Entrada Therapeutics, Inc. does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does TRDA have?

Accepted Answer

In its latest reporting period, Entrada Therapeutics, Inc. generated $-0.13B in Free Cash Flow against a total debt load of $0.05B.

Question 8

What is the Price-to-Book (P/B) ratio of Entrada Therapeutics, Inc.?

Accepted Answer

The Price-to-Book (P/B) ratio for Entrada Therapeutics, Inc. (TRDA) is currently 1.88.

Question 9

What is the Price-to-Sales (P/S) ratio of TRDA?

Accepted Answer

Based on trailing twelve-month data, Entrada Therapeutics, Inc. (TRDA) trades at a Price-to-Sales (P/S) ratio of 20.90.

Question 10

What is Entrada Therapeutics, Inc.'s Return on Equity (ROE)?

Accepted Answer

Entrada Therapeutics, Inc. (TRDA) has a Return on Equity (ROE) of -39.83%, representing its profitability relative to shareholder equity.